These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 19529746)

  • 1. The challenge of HIV-1 antiretroviral resistance in Africa in the era of HAART.
    Sendagire H; Easterbrook PJ; Nankya I; Arts E; Thomas D; Reynolds SJ
    AIDS Rev; 2009; 11(2):59-70. PubMed ID: 19529746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV antiretroviral drug resistance in Africa.
    Nkengasong JN; Adje-Toure C; Weidle PJ
    AIDS Rev; 2004; 6(1):4-12. PubMed ID: 15168736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analyses of HIV-1 drug-resistance profiles among infected adolescents experiencing delayed antiretroviral treatment switch after initial nonsuppressive highly active antiretroviral therapy.
    Agwu A; Lindsey JC; Ferguson K; Zhang H; Spector S; Rudy BJ; Ray SC; Douglas SD; Flynn PM; Persaud D;
    AIDS Patient Care STDS; 2008 Jul; 22(7):545-52. PubMed ID: 18479228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discordance between genotypic resistance and pseudovirus phenotypic resistance in AIDS patients after long-term antiretroviral therapy and virological failure.
    Yang J; Geng W; Zhang M; Han X; Shang H
    J Basic Microbiol; 2014 Oct; 54(10):1120-5. PubMed ID: 24338739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 drug resistance and associated factors among adults failing first-line highly active antiretroviral therapy in Ho Chi Minh City, Vietnam.
    Pham QD; Huynh TK; Luong TT; Tran T; Vu TX; Truong LX
    HIV Clin Trials; 2013; 14(1):34-44. PubMed ID: 23372113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting antiretroviral drug resistance from the latest or the cumulative genotype.
    Garcia F; Alvarez M; Fox Z; Garcia-Diaz A; Guillot V; Johnson M; Chueca N; Phillips A; Hernández-Quero J; Geretti AM
    Antivir Ther; 2011; 16(3):373-82. PubMed ID: 21555820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiretroviral resistance.
    Geretti AM
    J HIV Ther; 2006 Dec; 11(4):72-3. PubMed ID: 17578209
    [No Abstract]   [Full Text] [Related]  

  • 9. Ultradeep sequencing of B and non-B HIV-1 subtypes: Viral diversity and drug resistance mutations before and after one month of antiretroviral therapy in naive patients.
    Epaulard O; Signori-Schmuck A; Larrat S; Kulkarni O; Blum MG; Fusillier K; Blanc M; Leclercq P; François O; Morand P
    J Clin Virol; 2017 Oct; 95():13-19. PubMed ID: 28830014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo emergence of drug-resistant mutations at less than 50 HIV-1 RNA copies/mL that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type-1-infected patients on highly active antiretroviral therapy.
    Elbeik T; Hoo BS; Campodonico ME; Dileanis J; Fay FF; Bortolozzi RL; Benetti MS; Fay OH; Marlowe N; Petrauskene O; Chernoff D; Smith L; Ng VL
    J Hum Virol; 2001; 4(6):317-28. PubMed ID: 12082398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy.
    Geretti AM; Fox ZV; Booth CL; Smith CJ; Phillips AN; Johnson M; Li JF; Heneine W; Johnson JA
    J Acquir Immune Defic Syndr; 2009 Dec; 52(5):569-73. PubMed ID: 19779307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapy.
    Wallis CL; Papathanasopolous MA; Fox M; Conradie F; Ive P; Orrell C; Zeinecker J; Sanne I; Wood R; McIntyre J; Stevens W;
    Antivir Ther; 2012; 17(2):313-20. PubMed ID: 22293461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa.
    Marconi VC; Sunpath H; Lu Z; Gordon M; Koranteng-Apeagyei K; Hampton J; Carpenter S; Giddy J; Ross D; Holst H; Losina E; Walker BD; Kuritzkes DR;
    Clin Infect Dis; 2008 May; 46(10):1589-97. PubMed ID: 18419495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revisiting the concept of a genetic barrier to resistance.
    Rusconi S
    J HIV Ther; 2006 Dec; 11(4):81-3. PubMed ID: 17578211
    [No Abstract]   [Full Text] [Related]  

  • 15. Utility of repeat genotypic resistance testing and clinical response in patients with three class resistance and virologic treatment failure.
    Badri SM; Adeyemi OM; Max BE; Hota BN; Barker DE
    AIDS Patient Care STDS; 2007 Aug; 21(8):544-50. PubMed ID: 17711379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evolution of HIV resistance mutations in the Valme referral center].
    Nogales MC; Castro C; Martín-Mazuelos E
    Enferm Infecc Microbiol Clin; 2007 Feb; 25(2):159. PubMed ID: 17288915
    [No Abstract]   [Full Text] [Related]  

  • 17. HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa.
    Kityo C; Thompson J; Nankya I; Hoppe A; Ndashimye E; Warambwa C; Mambule I; van Oosterhout JJ; Wools-Kaloustian K; Bertagnolio S; Easterbrook PJ; Mugyenyi P; Walker AS; Paton NI;
    J Acquir Immune Defic Syndr; 2017 Jun; 75(2):e45-e54. PubMed ID: 28129253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minority HIV-1 resistant variants in recent infection and in patients who failed first-line antiretroviral therapy with no detectable resistance-associated mutations in Thailand.
    Le Nguyen H; Pitakpolrat P; Sirivichayakul S; Delaugerre C; Ruxrungtham K
    J Med Virol; 2012 May; 84(5):713-20. PubMed ID: 22431018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of minority populations of HIV type-1 with K103N and M184V drug resistance mutations among children in Argentina.
    Vignoles M; Barboni G; Agosti MR; Quarleri J; García MK; Ayala SG; Salomón H
    Antivir Ther; 2009; 14(8):1175-81. PubMed ID: 20032547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy.
    Wirden M; Delaugerre C; Marcelin AG; Ktorza N; Ait Mohand H; Dominguez S; Schneider L; Ghosn J; Pauchard M; Costagliola D; Katlama C; Calvez V
    Antimicrob Agents Chemother; 2004 Feb; 48(2):644-7. PubMed ID: 14742228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.